PEAK6 Group’s Adverum Biotechnologies ADVM Stock Holding History

PEAK6 Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,750	Closed	-$556K	–	4657
2015 Q3	$556K	Buy	+6,750	New	+$862K	﹤0.01%	2789

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

PEAK6 Group's ADVM Position: Q4 2015 in Review

PEAK6 Group sold out of Adverum Biotechnologies (ADVM) in Q4 2015, closing a stake of 8,707 shares — an estimated $717K sold.

PEAK6 Group first reported a position in ADVM in Q3 2015 and held it in 1 quarter. The position peaked at $717K in Q3 2015. 76 funds tracked by Wall St. Rank hold ADVM as of Q4 2015.

PEAK6 Group reported no remaining Adverum Biotechnologies position as of Q4 2015 after selling out during the quarter.
PEAK6 Group sold 8,707 Adverum Biotechnologies shares in Q4 2015, an estimated $717K.
PEAK6 Group first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 1 quarter.
PEAK6 Group's Adverum Biotechnologies position peaked at $717K in Q3 2015.
76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.